Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) announced its participation in the DealFlow Discovery Conference scheduled for January 28-29, 2026, in Atlantic City, New Jersey. The clinical-stage pharmaceutical company will have Chief Executive Officer Geordan Pursglove conducting one-on-one meetings with investors during the event. This investor outreach comes as Lixte continues advancing LB-100, its first-in-class inhibitor of protein phosphatase 2A (PP2A), through clinical development.
The company's participation in this investment conference holds significance for both investors and the oncology field as Lixte pursues what it describes as a pioneering effort in cancer biology called activation lethality. This new treatment paradigm represents a departure from traditional approaches and is covered by what the company calls a comprehensive patent portfolio. For investors, the conference provides direct access to company leadership during a critical phase of clinical development.
Lixte has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity. The company's research, detailed on its website at https://www.lixte.com, indicates that LB-100 has the potential to significantly enhance both chemotherapies and immunotherapies, potentially improving outcomes for cancer patients. This dual enhancement capability could address significant limitations in current cancer treatment protocols.
Proof-of-concept clinical trials are currently in progress for two specific cancer types: Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. These trials represent critical milestones in validating the company's approach and determining the therapeutic potential of LB-100. The selection of these particular cancers for initial trials suggests strategic targeting of conditions with significant unmet medical needs.
The company maintains its newsroom at http://ibn.fm/LIXT where investors can access the latest updates and information. For the broader investment community, the DealFlow Discovery Conference represents an opportunity to engage directly with a company developing what it describes as a first-in-class therapy in an entirely new field of cancer biology. The conference participation comes at a time when Lixte is moving through clinical validation stages that will determine the commercial viability of its approach.
InvestorWire, the platform distributing this announcement, provides specialized communications services for public and private companies seeking to reach investment audiences. More information about their services is available at https://www.InvestorWire.com. The convergence of investor communication and clinical advancement highlights the interconnected nature of pharmaceutical development and capital markets, particularly for companies developing novel therapeutic approaches that require substantial investment to reach patients.
